273 related articles for article (PubMed ID: 35958586)
1. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
Front Immunol; 2022; 13():954616. PubMed ID: 35958586
[TBL] [Abstract][Full Text] [Related]
2. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
3. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
4. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
6. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
Sun S; Wang Y; Wang J; Bi J
J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
[TBL] [Abstract][Full Text] [Related]
7. An EMT-related gene signature for the prognosis of human bladder cancer.
Cao R; Yuan L; Ma B; Wang G; Qiu W; Tian Y
J Cell Mol Med; 2020 Jan; 24(1):605-617. PubMed ID: 31657881
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
10. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
PeerJ; 2023; 11():e15284. PubMed ID: 37123010
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
13. Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
Zhou J; Zhou R; Zhu Y; Deng S; Muhuitijiang B; Li C; Shi X; Zhang L; Tan W
J Exp Clin Cancer Res; 2024 Apr; 43(1):101. PubMed ID: 38566204
[TBL] [Abstract][Full Text] [Related]
14. An Epithelial-Mesenchymal Transition (EMT) Preoperative Nomogram for Prediction of Lymph Node Metastasis in Bladder Cancer (BLCA).
Cao R; Ma B; Wang G; Xiong Y; Tian Y; Yuan L
Dis Markers; 2020; 2020():8833972. PubMed ID: 33204364
[TBL] [Abstract][Full Text] [Related]
15. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
16. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
Xiao Z; Cai Z; Deng D; Tong S; Zu X
Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
[TBL] [Abstract][Full Text] [Related]
17. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
18. An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer.
Tong H; Li T; Gao S; Yin H; Cao H; He W
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33289830
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
20. Identification of an EMT-related gene-based prognostic signature in osteosarcoma.
Gong H; Tao Y; Xiao S; Li X; Fang K; Wen J; Zeng M; Liu Y; Chen Y
Cancer Med; 2023 Jun; 12(11):12912-12928. PubMed ID: 37102261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]